FH and hereditary leiomyomatosis and renal cell cancer: For example, two clinical trials are looking specifically at HLRCC-based therapies on the hypothesis that metabolic alterations secondary to FH inactivation would be susceptible to the VEGF inhibitor bevacizumab and the EGFR TKI erlotinib.